Previous 10 | Next 10 |
Biostage Announces $5.1 Million Financing to Advance Clinical Trial PR Newswire HOLLISTON , Mass. , May 13, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-...
Biostage Schedules Conference Call and Webcast for Q1 2022 Results PR Newswire HOLLISTON, Mass. , May 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human...
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus PR Newswire Extends Core Intellectual Property coverage for treatment of lung cancer as well as esophageal cancer. HOLLISTON, Mass. , April 11...
Biostage press release (OTC:BSTG): Q4 GAAP EPS of -$0.55. The company expects that operating cash on-hand as of December 31, 2021 of $1.2M will enable us to fund operating expenses and capital expenditure requirements into early third quarter of 2022. For further details see: Biostage G...
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results PR Newswire HOLLISTON, Mass. , April 1, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successfu...
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results PR Newswire HOLLISTON, Mass. , March 30, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy ...
Biostage Announces "Meet the Founder, New Chairman and Interim CEO" Webinar Thursday, Jan. 27. 2-3pm ET via Zoom Thursday, Jan. 27. 8-9pm ET / 9-10am Friday, January 28 Beijing Time via Zoom PR Newswire HOLLISTON, Mass. , Jan. 25, 2022 /PRNewswire/ -- ...
Biostage Announces Court's Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense Court holds that Biostage's insurer breached its duty to defend a litigation from the estate of a patient who died after being treated with a Biostage Tracheal ...
New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets Establishes the basis for a clinical trial in human babies with birth defects in the esophagus. PR Newswire HOLLISTON, Mass. , Jan. 10, 2022 /PRNewswire/ -- Biostage, Inc. ...
Biostage (OTC:BSTG) hires David Green as its CEO and appointed Mr. Green as Chairman of the Board of Directors. Mr. Green is the founder and CEO of Zero CarbonTM LLC, an energy-efficiency business. He is also the former CEO and Chairman of Biostage, he resig...
News, Short Squeeze, Breakout and More Instantly...
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024. Received $0.5 million in convertible debt from Company’s CEO in February 2024. Hollisto...
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following Colectomy Established a Collaboration with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproduct...
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate o...